

ASX ANNOUNCEMENT

23 September 2020

**Respiri to provide shareholder update via Zoom call**

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, would like to provide shareholders, and other interested parties, an update on the Company’s operations. This update will be delivered via Zoom.

Along with the update to be provided by the CEO, Respiri is also giving shareholders the opportunity to ask questions. Please email your questions to the Company Secretary [alastair@respiri.co](mailto:alastair@respiri.co) at least one hour before the start of the meeting. Alternatively, you may submit questions during the meeting using the Zoom “chat” function. Questions via the Chat function should be directed to the participant called “Submit questions Here”.

Due to the difficulties of having a large number of attendees on a Zoom call, participants will unfortunately not have the opportunity to speak during the call.

The update will be held at 4:30pm AEST/Melbourne **today**, Wednesday 23 September 2020.

**Zoom details:**

Topic: Respiri Limited Shareholder Update

Time: Sep 23, 2020 04:30 PM Canberra, Melbourne, Sydney

Join Zoom Meeting

<https://us02web.zoom.us/j/87887621149>

**Meeting ID:** 878 8762 1149

**Passcode:** 145586

Dial by your location

+61 3 7018 2005 Australia

+61 7 3185 3730 Australia

+61 8 6119 3900 Australia

+61 8 7150 1149 Australia

+61 2 8015 6011 Australia

+44 203 051 2874 United Kingdom

+1 929 205 6099 US (New York)

Meeting ID: 878 8762 1149

Passcode: 145586

Find your local number: <https://us02web.zoom.us/u/kc8Z2fyC6g>

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

wheezo™ is a trademark of Respiri Limited.

*This ASX announcement dated 23 September 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

### **About Respiri Limited**

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)

### **About wheezo**

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.